Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. A high percentage of isoniazid resistance is linked to mutations in t...
Main Authors: | María Martínez-Hoyos, Esther Perez-Herran, Gulcin Gulten, Lourdes Encinas, Daniel Álvarez-Gómez, Emilio Alvarez, Santiago Ferrer-Bazaga, Adolfo García-Pérez, Fátima Ortega, Iñigo Angulo-Barturen, Joaquin Rullas-Trincado, Delia Blanco Ruano, Pedro Torres, Pablo Castañeda, Sophie Huss, Raquel Fernández Menéndez, Silvia González del Valle, Lluis Ballell, David Barros, Sundip Modha, Neeraj Dhar, François Signorino-Gelo, John D. McKinney, Jose Francisco García-Bustos, Jose Luis Lavandera, James C. Sacchettini, M. Soledad Jimenez, Nuria Martín-Casabona, Julia Castro-Pichel, Alfonso Mendoza-Losana |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396416301906 |
Similar Items
-
Estudo da resistência à isoniazida em Mycobacterium tuberculosis: uma caracterização estrutural e biofísica de mutações missense no gene inhA identificados a partir de isolados clínicos.
by: Pacheco, Sair Maximo Chavez
Published: (2018) -
Contribution of katG, ahpC and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates from Lebanon and Syria
by: F Dabboussi, et al.
Published: (2015-01-01) -
Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic
by: Jainagul Isakova, et al.
Published: (2018-03-01) -
In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors
by: Tarek S. Ibrahim, et al.
Published: (2020-07-01) -
New InhA Inhibitors Based on Expanded Triclosan and <i>Di</i>-Triclosan Analogues to Develop a New Treatment for Tuberculosis
by: Sarentha Chetty, et al.
Published: (2021-04-01)